EPO and anemia (phenotype): Anemia management through recombinant human erythropoietin (rhEPO) or erythropoiesis stimulating agents (ESAs) greatly benefits patients with CKD by improving their debilitating symptoms, and relieving them from dependence on blood transfusions [4].